Neurology

Uzm. Dr. Duygu Özkan Yaşargün

Doctor and researcher Haydarpaşa Numune Eğitim ve Araştırma Hastanesi İstanbul
Multiple Sclerosis
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyNeurologysaglik.gov.trFrom source
  • InstitutionHaydarpaşa Numune Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workMultiple SclerosisExtracted from 2 publications · Model version —From source
  • Publications19 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0003-3723-6335ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://haydarpasanumuneah.saglik.gov.tr/TR-1496317/doktorlarimiz.html#duygu-ozkan-yasargunsaglik.gov.tr

Scientific work

Publications on Multiple Sclerosis

19 publications
Publications by year Most: 5, in 2026
  1. 2014: 1 publication
  2. 2015: 1 publication
  3. 2016: 0 publications
  4. 2017: 2 publications
  5. 2018: 3 publications
  6. 2019: 0 publications
  7. 2020: 0 publications
  8. 2021: 0 publications
  9. 2022: 0 publications
  10. 2023: 1 publication
  11. 2024: 2 publications
  12. 2025: 4 publications
  13. 2026: 5 publications

  1. From seropositivity to neurosyphilis: clinical spectrum and diagnostic classification in hospitalized neurology patients: a 16-year retrospective study

    Frontiers in Neurology, 2026

    DOI 10.3389/fneur.2026.1911231 PMID 42712414 Open-access full textSource: ORCID

  2. From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing—Remitting Multiple Sclerosis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15135121 PMID 42452581 Open-access full textSource: ORCID

  3. Association of Molecular Biomarkers With Disease Prognosis and Brain Volume in RRMS Patients (P8-19.004)

    Neurology, 2026

    DOI 10.1212/wnl.0000000000215383 Source: ORCID

  4. Expression Levels of Intracellular Pathway Factors of B Lymphocytes in Patients with Multiple Sclerosis with and without Optic Neuritis Onset

    Journal of Multiple Sclerosis Research, 2026

    DOI 10.4274/jmsr.galenos.2026.2025-8-3 Open-access full textSource: ORCID

  5. Environmental Seizure Triggers and Ongoing Seizure Activity in Adults with Epilepsy

    Haydarpaşa Numune medical journal (Online), 2026

    DOI 10.14744/hnhj.2026.17037 Open-access full textSource: OpenAlex

  6. B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis.

    In vivo (Athens, Greece), 2025

    DOI 10.21873/invivo.13920 PMID 40010950 1 citation (Europe PMC) Open-access full textSource: ORCID

  7. Assessment of short-term ocrelizumab treatment impact on regulatory immune cell subsets through intracellular cytokine measurement in patients with multiple sclerosis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Source: ORCID

  8. Baseline eronufilmniaet light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis

    Turkish journal of medical sciences, 2025

    DOI 10.55730/1300-0144.6067 PMID 41234467 Open-access full textSource: ORCID

  9. Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks

    Noro psikiyatri arsivi, 2025

    DOI 10.29399/npa.28978 PMID 41383899 Open-access full textSource: ORCID

  10. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study

    European neurology, 2024

    DOI 10.1159/000539376 PMID 38754397 1 citation (Europe PMC) Open-access full textSource: ORCID

View all 19 publications